Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04493216 · ClinicalTrials.gov registry record · Phase 2
A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults
A Phase 2 study, sponsored by ViiV Healthcare.
- Terminated
- Registry status
- Phase 2
- Development phase
- 161
- Enrollment target
NCT04493216 is a Phase 2 study that was terminated before completion, run by ViiV Healthcare. The registered enrollment target is 161 participants.
The verdict
NCT04493216, a Phase 2 study, was terminated before completion, sponsored by ViiV Healthcare.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 161 participants
- Enrollment target
Study Summary
This is a phase 2b, randomized, multicenter, parallel group, partially blind (to GSK3640254 doses \[100, 150 and 200 milligrams {mg}\]), active controlled clinical trial. It aims to investigate the safety, efficacy and dose-response of GSK3640254 compared to dolutegravir (DTG), each given in combination with 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) (abacavir/lamivudine \[ABC/3TC\] or emtricitabine/tenofovir alafenamide \[FTC/TAF\]).
Interventions
- DRUG Placebo
- DRUG Dolutegravir
- DRUG FTC/TAF
- DRUG GSK3640254
- DRUG ABC/3TC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2020-11-18 |
| Est. Completion | 2023-05-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04493216
The ClinicalTrials.gov registry entry for NCT04493216 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT04493216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04493216 about?
NCT04493216 is a clinical study titled "A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults". This is a phase 2b, randomized, multicenter, parallel group, partially blind (to GSK3640254 doses \[100, 150 and 200 milligrams {mg}\]), active controlled clinical trial. It aims to investigate the safety, efficacy and dose-response of GSK3640254 compared to dolutegravir (DTG), each given in combina...
What is the current status of trial NCT04493216?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 161 participants. The study started on 2020-11-18. Estimated completion is 2023-05-29.
What interventions are being tested in trial NCT04493216?
The interventions under investigation include: Placebo (DRUG), Dolutegravir (DRUG), FTC/TAF (DRUG), GSK3640254 (DRUG), ABC/3TC (DRUG).
Who is sponsoring clinical trial NCT04493216?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.